Clinical Image Library – DiscoveryTM MI
Small Lesion
Small Lesion Detectability #1
Patient History
Patient with history of Melanoma referred to PET/CT for restaging and metastatic evaluation.
Patient BMI
22.6
Acquisition
15 minutes
298 MBq / 8 mCi FDG
96 minute uptake
Conclusion
DISCOVERY MI sensitivity and LightBurst Digital Detector simultaneously provide excellent image quality and
resolution. Discovery MI enables greater confidence when looking for small metastatic disease in difficult areas
such as the liver.
Courtesy of Stanford University, A. Iagaru, MD
Follow-up contrast enhanced CT confirms the presence of a small lesion detected by Discovery MI's digital PET detection technology.
Small Lesion Detectability #2
Patient History
Patient with history of Head and Neck cancer referred to PET/CT to evaluate extent of disease and lymph node
involvement.
Patient BMI
25.6
Acquisition
2 minutes / FOV
329 MBq / 8.9 mCi FDG
65 minute uptake
Conclusion
Discovery MI sensitivity and LightBurst Digital Detector simultaneously provide excellent image quality and
resolution. Discovery MI provides excellent small lesion detectability for assessing small lymph node involvement
in the Head and Neck area.
Courtesy University of Zurich
Small Lesion Detectability #3
Patient History
Patient with history of Prostate cancer referred to PET/CT with new bone pain. Evaluation of metastatic disease.
Patient BMI
27.4
Acquisition
25 minutes
270 MBq / 7.3 mCi 18F - NAF
113 minute uptake
Conclusion
Discovery MI sensitivity and clinical resolution provide small lesion detectability for small bone lesions.
Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Small Lesion Detectability #4
Low noise imaging demonstrates excellent image quality / small lesion detectability.
Courtesy Stanford University, A. Iagaru, MD. PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Advanced CT
Advanced CT
Patient History
Patient referred to PET/CT for evaluation of bone formation around prothesis and assessment of inflammation.
Acquisition
298 MBq / 8 mCi NaF
96 minute uptake
CT Reconstruction with Smart MAR
PET Reconstruction with Q.Clear
Courtesy PET Center Uppsala
High Count Rate Tracers
High Count Rate Tracers #1
Patient History:
73-year-old patient with history of
HTN, DM and CAD with prior LAD PCI
and Stent. Referred to PET/CT for
dyspnea and chest heaviness.
Patient BMI:
27.8
Acquisition:
20 minute dynamic 13N-Ammonia
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest
Courtesy Stanford University, G. Davidzon, MD
High Count Rate Tracers #2
Patient History:
Patient referred to Cardiac PET/CT to evaluate chest pain. No history of previous CAD.
Acquisition:
5 minute 15O-Water
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest
Findings
Proximal LAD shows 54% stenosis on CTA which corresponds to anteroseptal perfusion defect on PET.
Courtesy of Uppsala University PET Center
Cardiac
Cardiac #1
Patient History:
Patient referred to PET/CT for
evaluation of Coronary Artery Disease.
Patient BMI:
28.1
Acquisition:
20 minute dynamic 13N - Ammonia
200 MBq / 5.4 mCi Stress
400 MBq / 10.8 mCi Rest
Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Cardiac #2
Patient History:
73-year-old patient with history of
HTN, DM and CAD with prior LAD PCI
and Stent. Referred to PET/CT for
dyspnea and chest heaviness.
Patient BMI:
27.8
Acquisition:
20 minute dynamic 13N-Ammonia
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest
Courtesy Stanford University, G. Davidzon, MD
Cardiac #3
Patient History:
Patient referred to Cardiac PET/CT to evaluate chest pain. No history of previous CAD.
Acquisition:
5 minute 15O-Water
400 MBq / 10.8 mCi Stress
400 MBq / 10.8 mCi Rest
Findings
Proximal LAD shows 54% stenosis on CTA which corresponds to anteroseptal perfusion defect on PET.
Courtesy of Uppsala University PET Center
Cardiac #4
Patient History:
Patient referred to Cardiac PET/CT
to evaluate myocardial viability
prior to intervention.
Patient BMI:
25.2
Acquisition:
5 minute Gated
5.42 mCi / 200 MBq 18F-FDG
60 minute uptake
Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Fast Scans
Fast Scans #1
½ Time1, No Compromise.
Discovery MI sensitivity and LightBurst Digital Detector provide reliable and consistent image quality, resolution and quantitative accuracy. With Discovery MI, a research center can
free up scanner time for its studies without impacting daily clinical workload.
Courtesy Stanford University, A. Iagaru, MD
1Compared to Discovery PET/CT 710
Fast Scans #2
Patient History
Patient referred to PET/CT for
evaluation and localization of
epilepsy foci.
Patient BMI
28.4
Acquisition
10 minute brain scan
2.5 mCi / 92.5 MBq FDG
45 minute uptake
Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Fast Scans #3
Patient History:
Patient referred to Cardiac PET/CT
to evaluate myocardial viability
prior to intervention.
Patient BMI:
25.2
Acquisition:
5 minute Gated
5.42 mCi / 200 MBq 18F-FDG
60 minute uptake
Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Low Dose
Low Dose #1
Patient History:
Patient referred to PET/CT for
evaluation and localization of
epilepsy foci.
Patient BMI
28.4
Acquisition
10 minute brain scan
2.5 mCi / 92.5 MBq FDG
45 minute uptake
Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Low Dose #2
Patient History:
Patient referred to PET/CT for
evaluation of Coronary Artery Disease.
Patient BMI:
28.1
Acquisition:
20 minute dynamic 13N - Ammonia
200 MBq / 5.4 mCi Stress
400 MBq / 10.8 mCi Rest
Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Low Dose #3
Patient History:
Patient referred to Cardiac PET/CT
to evaluate myocardial viability
prior to intervention.
Patient BMI:
25.2
Acquisition:
5 minute Gated
5.42 mCi / 200 MBq 18F-FDG
60 minute uptake
Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Low Dose #4
Ga-68 DOTATATE
Left
- 78 minute uptake
- 2.6 mCi / 96 MBq at scan time
Right
- 104 minute uptake
- 2.2 mCi / 81 MBq at scan time
Courtesy Stanford University, A. Iagaru, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Low Dose #5
Patient History
Patient with history of HCC treated with Y-90 TheraSpheres. PET/CT for post-treatment verification.
Patient BMI
20.6
Acquisition
15 minute scan
Y-90 TheraSpheres
91.94 mCi / 3.4 GBq
Courtesy Stanford University, S. Srinivas, MD
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Neurology
Neurology #1
Patient History
Patient referred to PET/CT for
evaluation and localization of
epilepsy foci.
Patient BMI
28.4
Acquisition
10 minute brain scan
2.5 mCi / 92.5 MBq FDG
45 minute uptake
Courtesy Zurich University
PET Radiopharmaceutical may not be approved by ministers of health in all regions.
Neurology #2
Patient History:
Patient referred to PET/CT for
evaluation of Parkinson's disorders.
Acquisition
11C-PE21-dynamic
study
Courtesy PET Center Uppsala.
PET Radiopharmaceutical may not be approved by ministers of health in all regions.